

Marta Bonotto

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8979817/marta-bonotto-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53
papers

839
citations

17
h-index

28
g-index

56
ext. papers

1,002
ext. citations

4.2
avg, IF

3.57
L-index

#	Paper	IF	Citations
53	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation.. <i>Oncologist</i> , 2022 ,	5.7	4
52	First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study. <i>Breast</i> , 2021 , 57, 104-112	3.6	2
51	Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
50	The SENECA study: Prognostic role of serum biomarkers in older patients with metastatic colorectal cancer. <i>Journal of Geriatric Oncology</i> , 2020 , 11, 1268-1273	3.6	2
49	Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study. <i>Future Oncology</i> , 2020 , 16, 2059-2073	3.6	1
48	Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis. <i>Scientific Reports</i> , 2020 , 10, 7010	4.9	8
47	Plasma-Based Longitudinal Evaluation of Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 550185	5.3	4
46	Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget disease of the vulva. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 1672-1677 ⁹	3.5	1
45	Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer. <i>Future Oncology</i> , 2020 , 16, 2645-2660	3.6	1
44	Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker. <i>Cancers</i> , 2019 , 11,	6.6	17
43	The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019 , 10, 368-377	10.3	36
42	Long-term toxicity profile of trastuzumab emtansine (T-DM1): A multicenter real-life study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e12507-e12507	2.2	2
41	Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey. <i>Breast</i> , 2018 , 40, 45-52	3.6	4
40	Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. <i>Breast</i> , 2018 , 38, 86-91	3.6	20
39	Determinants of Last-line Treatment in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018 , 18, 205-213	3.3	7
38	Prognostic role of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in metastatic breast cancer (MBC) patients: First clues for cost-effective biomarkers.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e13079-e13079	2.2	2
37	Association of clinical factors and biological subtypes with different Ca15-3 levels in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e24014-e24014	2.2	

36	Integration of lymphocyte ratios (LRs) and circulating tumor cells (CTCs) characterization: The interplay between immunity and metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12039-12039	2.2	
35	Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 365-374	5.4	23
34	Immunotherapy for colorectal cancer: where are we heading?. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 709-721	5.4	71
33	Immunotherapy for gastric cancers: emerging role and future perspectives. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 609-619	3.8	26
32	Androgen receptor in estrogen receptor positive breast cancer: Beyond expression. <i>Cancer Treatment Reviews</i> , 2017 , 61, 15-22	14.4	30
31	Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. <i>Breast</i> , 2017 , 31, 114-120	3.6	42
30	Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors. <i>Future Oncology</i> , 2017 , 13, 135-144	3.6	8
29	Molecular classifications of gastric cancers: Novel insights and possible future applications. <i>World Journal of Gastrointestinal Oncology</i> , 2017 , 9, 194-208	3.4	38
28	Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis. <i>Oncotarget</i> , 2017 , 8, 112816-112824	3.3	1
27	Setting and timing of end-of-life care in cancer patients.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e21502-e21502		
26	Determinants of adjuvant chemotherapy use in small luminal-like breast cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e12010-e12010	2.2	
25	Preliminary results from CAMEO-PRO study: Complementary and alternative medicine in oncology physicians inform oncological patients.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e21632-e21632	2.2	
24	Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy. <i>Clinical Colorectal Cancer</i> , 2016 , 15, 7-15	3.8	3
23	The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. <i>British Journal of Cancer</i> , 2016 , 115, 1471-1478	8.7	29
22	The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors. <i>Expert Review of Molecular Diagnostics</i> , 2015 , 15, 979-87	3.8	11
21	Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 165-78	7	24
20	Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?. <i>Oncologist</i> , 2015 , 20, 719-24	5.7	40
19	Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 1185-98	5.9	4

18	Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials. <i>Oncotarget</i> , 2015 , 6, 28716-30	3.3	9
17	Looking for predictive markers in breast cancer. <i>Lancet Oncology</i> , 2015 , 16, e1	21.7	7
16	Pattern of metastasis and outcome in patients with breast cancer. <i>Clinical and Experimental Metastasis</i> , 2015 , 32, 125-33	4.7	101
15	Endocrine maintenance therapy in luminal breast cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e11578-e11578	2.2	6
14	Treatment during the last month of life in advanced cancer patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17649-e17649	2.2	6
13	Endocrine therapy and chemotherapy in luminal metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e11573-e11573	2.2	6
12	The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. <i>Expert Opinion on Investigational Drugs</i> , 2014 , 23, 925-42	5.9	28
11	Measures of outcome in metastatic breast cancer: insights from a real-world scenario. <i>Oncologist</i> , 2014 , 19, 608-15	5.7	143
10	Pattern of metastatic spread and prognosis of breast cancer biologic subtypes.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e12532-e12532	2.2	6
9	Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients. <i>Current Drug Targets</i> , 2014 , 15, 1225-30	3	7
8	Differences in hormonal receptor status and Ki67 expression between primary breast cancer and metastasis: Is variation related to previous therapy?. <i>Journal of Clinical Oncology</i> , 2014 , 32, e22006-e22006	2.2	6
7	Advanced luminal breast cancer: Who receives chemotherapy as first-line systemic treatment?. <i>Journal of Clinical Oncology</i> , 2014 , 32, e11524-e11524	2.2	6
6	Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use. <i>Drugs</i> , 2013 , 73, 2003-15	12.1	40
5	Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase?. <i>Clinical Breast Cancer</i> , 2013 , 13, 167-72	3	18
4	Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. <i>World Journal of Gastroenterology</i> , 2013 , 19, 8474-88	5.6	8
3	Endocrine therapy in patients with metastatic breast cancers (MBC): Prognosis and measures of outcome.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e13070-e13070	2.2	6
2	Tailored endpoints: A proposal for design of future clinical trials in metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, e13058-e13058	2.2	6
1	Association of body mass index and outcome in advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1044-1044	2.2	6

